Obese Children and Adolescents Have Elevated Nighttime Blood Pressure Independent of Insulin Resistance and Arterial Stiffness

Kristian N. Hvidt, 1,2 Michael H. Olsen, 3 Jens-Christian Holm, 2 and Hans Ibsen 1

BACKGROUND
Insulin resistance has been related to elevated blood pressure (BP) in obese children and may adversely affect the vasculature by arterial stiffening. The objective was to investigate whether daytime and nighttime BP were elevated and related to insulin resistance and arterial stiffness in obese children and adolescents.

METHODS
Ninety-two obese patients aged 10–18 years were compared with 49 healthy control individuals. Insulin resistance was measured as the homeostatic assessment model (HOMA), and arterial stiffness was measured as carotid–femoral pulse wave velocity (cfPWV).

RESULTS
Mean ± SD daytime systolic BP (SBP) (obese: 125 ± 8.3 mm Hg; control: 121 ± 10.1 mm Hg; P = 0.03) and nighttime SBP (obese: 108 ± 10.7 mm Hg; control: 102 ± 8.2 mm Hg; P = 0.0001) were higher in the obese group when compared with the control group. No difference was found in daytime diastolic BP (DBP), whereas nighttime DBP (obese: 60 ± 6.6 mm Hg; control: 57 ± 4.8 mm Hg; P = 0.001) and night-to-day BP ratios were higher in the obese group. Nighttime SBP was related to BMI z score (β = 6.0; 95% confidence interval (CI) = 2.9–9.1; P = 0.0002) and waist/height ratio (β = 36.7; 95% CI = 5.6–67.9; P = 0.02) in the obese group. HOMA index (obese: median = 3.7, interquartile range (IQR) = 2.3–6.0; control: median = 2.6, IQR = 1.8–3.4; P = 0.002) was higher, whereas cfPWV (obese: 4.8 ± 0.8 m/s; control: 5.1 ± 0.6 m/s; P = 0.03) was lower in the obese group. CfPWV was not related to logHOMA index. In multiple regression analyses, the higher nighttime BP in the obese group was independent of logHOMA and cfPWV.

CONCLUSIONS
Obese children had a higher nighttime BP when compared with the control group independently of insulin resistance and arterial stiffness. No relationship was found between insulin resistance and arterial stiffness.

CLINICAL TRIAL REGISTRATION
Clinicaltrials.gov identifier NCT01310088

Keywords: adolescence; ambulatory blood pressure monitoring; arterial stiffness; blood pressure; children; hypertension; microalbuminuria; nighttime; obesity; pulse wave velocity.

doi:10.1093/ajh/hpu055

Obesity-related elevated blood pressure (BP) has been linked to insulin resistance in children and adolescents. 1–3 In this respect, insulin resistance may impact the cardiovascular system, contributing to the obesity-related elevated BP. 1 The adverse effect associated with insulin resistance could be arterial wall stiffening (arterial stiffness) 5,6 and universal microvascular damage. 7–9 Carotid–femoral pulse wave velocity (cfPWV) is the gold standard for measuring arterial stiffness. 10 Microalbuminuria (i.e., slightly elevated excretion of urinary albumin) is a marker of glomerular damage, as well as a marker of universal microvascular damage. 11,12

Ambulatory BP monitoring (ABPM) is regarded as the most precise measure of the BP burden, 13 and focus on nighttime BP is growing because of its significant prognostic role. 14 The focus on nighttime BP is also anticipated to be relevant among children and adolescents. 15 The relationships between insulin resistance, microalbuminuria, arterial stiffness, and their influence on ABPM are unclear in obese children and adolescents.

The objective of this study was to investigate whether daytime and nighttime BP are elevated in obese children and adolescents when compared with a nonobese control group and, if so, whether these ambulatory BP levels
are related to insulin resistance, arterial stiffness, and/or microalbuminuria.

METHODS

Design and participants

Our cross-sectional study design has been described in a recent publication. Briefly, severely obese white patients aged 10–18 years were recruited at inclusion to the Children's Obesity Clinic, Department of Pediatrics, Holbaek University Hospital. Age- and sex-matched white control individuals were recruited from the local area. All measures were performed on 2 consecutive days. Blood sampling was performed in proximity to inclusion in the Children's Obesity Clinic as part of the treatment protocol.

Data in this study is constrained to 92 patients in the obese group (89% of the initial included patients) and 49 individuals in the control group (98% of the control individuals) with valid ABPM and no signs of secondary hypertension.

Use of medication (yes vs. no) was recorded in 5 obese and 4 control individuals with a history of asthma or allergy symptoms, 3 obese individuals with gastrointestinal symptoms, 3 obese individuals and 1 control individual with hormonal supplementation, 3 obese individuals on birth control medication, and 3 obese and 5 control individuals receiving other not specified medications.

The study was declared to ClinicalTrials.gov (NCT01310088) and the Danish Data Agency and approved by the Scientific Ethical Committee of Region Zealand. Written informed consent was obtained from parents and individuals aged 18 according to the Helsinki Declaration.

Obesity measures

Height was measured to the nearest 0.1 cm and weight to the nearest 0.1 kg wearing light indoor clothes without shoes using an integrated calibrated weight and stadiometer (Model MZ10023, ADE, Hamburg, Germany). Body mass index (BMI; kg/m²) was calculated into BMI z scores in respect to a Danish standard population with the same age and sex. Waist circumference was measured to the nearest 0.1 cm with subjects standing using a stretch-resistant tape. Waist/height ratio (WHR) was calculated.

Clinic and ambulatory BP

Brachial clinic BP was measured after a rest of 10 minutes in supine position with the oscillometric device Omron 705IT (Omron Healthcare Europe, Gl Hoofddorp, The Netherlands) using cuff sizes as recommended by the manufacturer: small (arm circumference <22 cm), medium (22–32 cm), and large (≥32 cm). Mean of the last 2 of 3 BP measurements was reported and calculated into z scores according to an American standard population based on individuals’ sex, age, and height.

Ambulatory BP was measured with the oscillometric device Boso TM-2430 (Bosch + Sohn GmbH u. Co. KG, Jungingen, Germany). The device was mounted on the upper brachial arm using cuff size as recommended by the manufacturer: small (arm circumference <22 cm), medium (22–32 cm), and large (≥32 cm). The device was programmed to measure with 15-minute intervals during the day (7 AM to 10 PM) and 30-minute intervals during the night. Individuals were asked to keep a diary of their sleep time interval to differentiate awake (daytime) from sleep (nighttime) in the BP analyses. Mean values of ambulatory BP and heart rate (HR) were calculated into z scores according to a German standard population based on individuals’ sex and height. Only individuals with valid ABPM with at least 20 valid BP measurements during the day and at least 7 at night were included in the analysis. Night-to-day BP ratio was calculated as nighttime BP divided by daytime BP.

The BP classification was based on cutoff levels for both clinic and 24-hour systolic and diastolic BP normotension (clinic and 24-hour BP <95th percentile), white-coat hypertension (clinic BP ≥95th percentile and 24-hour BP <95th percentile), masked hypertension (clinic BP <95th percentile and 24-hour BP ≥95th percentile), and hypertension (clinic and 24-hour BP ≥95th percentile). The 95th percentile equals a z score of 1.645.

Subclinical organ markers

Arterial stiffness was measured as cfPWV by noninvasive applanation tonometry using the SphygmoCor 9.0 device (AtCor Medical, Sydney, Australia). CcfPWV was computed as pulse wave travel distance divided by pulse wave transit time. Travel distance was measured with a caliper, being 80% of the direct distance from the carotid artery to the femoral artery. The transit time was determined from the carotid and femoral arterial waveforms recorded consecutively with an electrocardiogram gated signal. The day-to-day variation (repeatability) of cfPWV was 0.3 ± 0.36 m/s (mean difference ± SD), and the measurements did not differ 2 days in between (P = 0.64) in a subsample of 25 of the obese patients.

Individuals were asked to refrain from smoking at least 3 hours before the cfPWV and clinic BP measurements. The corresponding author performed all anthropometric, clinic BP, and cfPWV measurements.

Venous blood samples were drawn early morning after overnight fasting. Biochemical plasma concentrations were measured by an enzymatic colorimetric method (Cobas 6000; F. Hoffmann-La Roche AG, Basel, Switzerland). However, plasma insulin in 6 of the obese blood samples was measured with the former laboratory method (Immulus 2000; Siemens Healthcare, Erlangen, Germany). Insulin resistance was determined as the homeostatic model assessment (HOMA) index calculated as glucose (mg/dl) multiplied by insulin (µIU/ml) and divided by 405. Plasma creatinine was measured by a colorimetric reaction with alkaline picrate (the Jaffe method) and automatically corrected by –26 µmol/L (Cobas 6000). Estimated glomerular filtration rate was calculated using the updated Schwartz’s formula applied for Jaffe methods: 0.55 × height (cm) / (plasma creatinine (µmol/L) / 76.46).

Microvascular damage was assessed as mean urine-albumin-creatinine ratio (UACR; mg/g) from 2 overnight urine
spot samples. Urine albumin concentration (mg/L) was measured by an immunoturbidimetric precipitation method (Konelab 30i, Thermo Fischer Scientific, Waltham, MA), whereas creatinine (mmol/L) was measured by an enzymatic method (Cobas 6000). Urine albumin and UACR was set to 0.1 (mg/L and mg/g) when albumin was below the detectable level of 1.0 mg/L. Microalbuminuria was defined as an UACR between 30 and 299 mg/g.12

Statistics

Statistical analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC). Differences between the obese and the control group were assessed by unpaired (2 sample) Student t tests for normally distributed continuous variables, otherwise by Wilcoxon rank sum tests, χ² tests for categorical variables, or Fischer exact tests when appropriate. Differences in ambulatory BP z scores between the obese and the control group were adjusted for age in multiple regression analyses. Cochran–Armitage trend test was used to test for a potential difference in the BP classification between the obese and the control group, whereas paired Student t tests were used for comparison of clinic and ambulatory BP.

In linear regression analyses, relationships between explanatory and dependent variables were investigated separately for the obese and the control group. Explanatory variables skewed to the right were log-transformed to fit models; otherwise Pearson correlation coefficient (r̂) was used. Potential sex differences in these potential relationships were investigated in multiple regression analyses.

Daytime and nighttime BP were related to a group variable (obese vs control individuals) in pooled multiple regression analyses when adjusting for subclinical organ markers (logHOMA index, cfPWV, and logUACR), as well as relevant confounders (sex, age, height, and period-dependent HR). Because of the design of the recruitment, the group variable encompasses the differences between the 2 groups in obesity measures (BMI z score and WHR). Avoiding overadjustment, these measures were not included in the analyses. To pool data from the obese and the control group, the regression models were tested for possible interaction of the group variable with the other explanatory variables. Furthermore, to pool data from male and female subjects, the multiple regression models were tested for possible interaction of the sex variable with the other explanatory variables. Finally, analyses comparing ambulatory BP between the obese and the control group were repeated when excluding smokers and individuals receiving medication.

RESULTS

Study design: obesity measures

The obese and the control groups were matched for age, sex, and height (Table 1). As expected because of the design of the recruitment, the obese group had higher weight, BMI, BMI z score, waist circumference, and WHR as compared with the control group.

Clinic and ambulatory BP

The obese group had higher levels of clinic systolic and diastolic BP when compared with the control group (Table 2).

Twenty-four-hour, daytime, and nighttime systolic BP, pulse pressure, and HR were consistently higher in the obese group when compared with the control group. No differences were found in 24-hour or daytime diastolic BP, whereas nighttime diastolic BP was higher in the obese group. Twenty-four-hour mean arterial pressure was higher in the obese group and apparently driven by a higher nighttime mean arterial pressure because no difference was found in daytime mean arterial pressure.

Differences in ambulatory and clinic BP z scores between the obese and the control group did not differ from differences in BPs in millimeters of mercury (Supplementary Tables S1 and S2). However, clinic systolic BP z scores were not significantly higher in the obese group. Ambulatory BP z scores were not related to age (Supplementary Table S2).

The variation of systolic and diastolic BP throughout the day in the 2 groups is plotted in Figure 1. The figure displays the relatively higher nighttime vs. daytime BP in the obese group when compared with the control group, also demonstrated by higher night-to-day BP ratios in the obese group (systolic BP: 0.864 ± 0.074 for obese vs. 0.835 ± 0.062 for control, P = 0.02; diastolic BP: 0.820 ± 0.103 for obese vs. 0.781 ± 0.082 for control, P = 0.02).

Table 1. Body composition

<table>
<thead>
<tr>
<th>Variable</th>
<th>Obese group (n = 92)</th>
<th>Control group (n = 49)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female sex, no.</td>
<td>42/50</td>
<td>22/27</td>
<td>0.93</td>
</tr>
<tr>
<td>Age, y</td>
<td>12.7 (11.4–14.9)</td>
<td>13.5 (11.7–14.9)</td>
<td>0.45</td>
</tr>
<tr>
<td>Height, cm</td>
<td>160.2 ± 11.6</td>
<td>163.3 ± 12.2</td>
<td>0.13</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>67.2 (58.3–90.7)</td>
<td>50.7 (41.3–58.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.3 (24.1–32.2)</td>
<td>18.9 (16.7–20.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI z score</td>
<td>2.73 ± 0.66</td>
<td>0.07 ± 0.85</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>94.7 (84.9–106.8)</td>
<td>66.3 (62.7–69.6)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>WHR</td>
<td>0.60 (0.56–0.64)</td>
<td>0.40 (0.38–0.42)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are mean ± SD or median (interquartile range) unless otherwise specified. Abbreviations: BMI, body mass index; WHR, waist/height ratio.
Table 2. Clinic and ambulatory blood pressure

<table>
<thead>
<tr>
<th>Variable</th>
<th>Obese group (n = 92)</th>
<th>Control group (n = 49)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic systolic BP, mm Hg</td>
<td>111 ± 9</td>
<td>107 ± 8</td>
<td>0.01</td>
</tr>
<tr>
<td>Clinic diastolic BP, mm Hg</td>
<td>62 ± 6</td>
<td>59 ± 5</td>
<td>0.006</td>
</tr>
<tr>
<td>24-hour systolic BP, mm Hg</td>
<td>121 ± 8</td>
<td>117 ± 9</td>
<td>0.002</td>
</tr>
<tr>
<td>24-hour diastolic BP, mm Hg</td>
<td>70 ± 5</td>
<td>69 ± 6</td>
<td>0.11</td>
</tr>
<tr>
<td>24-hour MAP, mm Hg</td>
<td>87 ± 5</td>
<td>85 ± 6</td>
<td>0.01</td>
</tr>
<tr>
<td>24-hour PP, mm Hg</td>
<td>51 ± 6</td>
<td>48 ± 6</td>
<td>0.002</td>
</tr>
<tr>
<td>Daytime systolic BP, mm Hg</td>
<td>125 ± 8</td>
<td>121 ± 10</td>
<td>0.03</td>
</tr>
<tr>
<td>Daytime diastolic BP, mm Hg</td>
<td>73 ± 6</td>
<td>73 ± 7</td>
<td>0.67</td>
</tr>
<tr>
<td>Daytime MAP, mm Hg</td>
<td>90 ± 6</td>
<td>89 ± 7</td>
<td>0.22</td>
</tr>
<tr>
<td>Daytime PP, mm Hg</td>
<td>52 ± 6</td>
<td>49 ± 7</td>
<td>0.005</td>
</tr>
<tr>
<td>Daytime HR, bpm</td>
<td>82 ± 8</td>
<td>78 ± 10</td>
<td>0.02</td>
</tr>
<tr>
<td>Nighttime systolic BP, mm Hg</td>
<td>108 ± 11</td>
<td>102 ± 8</td>
<td>0.0001</td>
</tr>
<tr>
<td>Nighttime diastolic BP, mm Hg</td>
<td>60 ± 7</td>
<td>57 ± 5</td>
<td>0.001</td>
</tr>
<tr>
<td>Nighttime MAP, mm Hg</td>
<td>76 ± 7</td>
<td>72 ± 6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Nighttime PP, mm Hg</td>
<td>48 ± 7</td>
<td>45 ± 6</td>
<td>0.004</td>
</tr>
<tr>
<td>Nighttime HR, bpm</td>
<td>70 ± 9</td>
<td>64 ± 9</td>
<td>0.0002</td>
</tr>
</tbody>
</table>

Data are mean ± SD.
Abbreviations: BP, blood pressure; HR, heart rate; MAP, mean arterial pressure; PP, pulse pressure.

Figure 1. Circadian variation of the ambulatory blood pressure (BP). Mean values of ambulatory systolic and diastolic BP for a given time plotted throughout the day in the obese and the control group. Time interval between BP readings was every 15 minutes during the daytime (7 AM to 10 PM) and every 30 minutes during the nighttime.
Twenty-four-hour BP was consistently higher than clinic BP in the obese group ($\Delta$systolic BP = 10.1 ± 8.0 mm Hg; $\Delta$diastolic BP = 8.4 ± 6.2 mm Hg; $P < 0.0001$ for both) and the control group ($\Delta$systolic BP = 9.3 ± 10.7 mm Hg; $\Delta$diastolic BP = 9.8 ± 6.6 mm Hg; $P < 0.0001$ for both). Twenty (22%) obese vs. 12 (24%) control individuals were classified as white-coat hypertensive. No overall difference was found in the BP classification as found by the Cochran–Armitage trend test ($P = 0.18$): 15 (16%) obese vs. 3 (6%) control individuals were hypertensive, 10 (11%) obese vs. 6 (12%) control individuals were masked hypertensive, and 47 (51%) obese vs. 29 (57%) controls individuals were normotensive.

**Metabolic factors and markers of subclinical organ damage**

CfPWV and fasting glucose were lower in the obese group (Table 3). Metabolic measures, including insulin, HOMA index, and lipids, were higher in the obese group vs. the control group, except for high-density lipoprotein cholesterol. No differences were found in UACR, urine albumin, or in the prevalence of microalbuminuria (obese: 2 (2%); control: 1 (2%); $P = 1.00$) between the 2 groups. Urine albumin was undetectable in more than half of the urine samples in both groups (obese: 103 (61%); control: 51 (56%); $P = 0.44$). Estimated glomerular filtration rate was higher in the obese group, whereas plasma creatinine was lower, when compared with the control group.

**Relationship between obesity measures and markers of subclinical organ damage**

LogHOMA index was related to BMI z score ($\beta = 0.25$, 95% confidence interval (CI) = 0.13–0.37; $P < 0.0001$) and WHR ($\beta = 2.52$, 95% CI = 1.39–3.65; $P < 0.0001$) in the obese group, whereas these relationships were not found in the control group. No significant sex differences were found in these relationships.

In the obese group, logUACR was related to logHOMA ($r_p = 0.36$; $P = 0.002$), whereas cfPWV was not ($\beta = -0.04$; 95% CI = −0.42 to 0.33; $P = 0.82$). In the control group, neither logUACR nor cfPWV was related to logHOMA index. No sex differences were found when cfPWV was related to logHOMA.

**Table 3.** Metabolic factors and markers of subclinical organ damage

<table>
<thead>
<tr>
<th>Variable</th>
<th>Obese group (n = 92)</th>
<th>Control group (n = 49)</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CfPWV, m/s</td>
<td>4.84 ± 0.57</td>
<td>5.08 ± 0.63</td>
<td>0.03</td>
</tr>
<tr>
<td>Fasting glucose, mg/dl</td>
<td>95.5 ± 10.8</td>
<td>100.9 ± 10.8</td>
<td>0.03</td>
</tr>
<tr>
<td>Insulin, µIU/ml</td>
<td>15.9 (9.5–26.0)</td>
<td>10.0 (7.1–14.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HOMA index</td>
<td>3.7 (2.3–6.0)</td>
<td>2.6 (1.8–3.4)</td>
<td>0.002</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl</td>
<td>162.2 (142.9–181.5)</td>
<td>142.9 (139.0–158.3)</td>
<td>0.005</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl</td>
<td>92.7 ± 27.0</td>
<td>77.2 ± 23.2</td>
<td>0.0002</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dl</td>
<td>50.2 ± 11.6</td>
<td>57.9 ± 11.6</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>79.6 (53.1–123.9)</td>
<td>61.9 (44.2–70.8)</td>
<td>0.0004</td>
</tr>
<tr>
<td>Creatinine, µmol/L</td>
<td>53.3 ± 9.3</td>
<td>61.2 ± 11.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73m²</td>
<td>128.9 ± 18.7</td>
<td>114.8 ± 15.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Urine albumin, mg/l</td>
<td>2.1 (0.1–9.5)</td>
<td>5.1 (0.1–10.0)</td>
<td>0.33</td>
</tr>
<tr>
<td>UACR, mg/g</td>
<td>1.6 (0.1–6.1)</td>
<td>2.8 (0.1–5.6)</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Data are mean ± SD or median (interquartile range). Because of either hemolysis of blood samples, no shows, or visit delay exceeding 60 days, the total number of blood samples were 79 (86%) in the obese and 47 (96%) in the control group, and the number of urine samples were 88 (98%) in the obese and 46 (94%) in the control group.

**Abbreviations:** CfPWV, carotid–femoral pulse wave velocity; eGFR, estimated glomerular filtration rate; HOMA index, homeostatic model assessment index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; UACR, urine-albumin-creatinine ratio.

Relationship between obesity measures and daytime and nighttime BP

In the obese group, no relationship was found between BMI z score or WHR and daytime systolic or diastolic BP. Daytime systolic BP tended to be related to BMI z score ($\beta = 2.3$, 95% CI = −0.2 to 4.9; $P = 0.08$). Nighttime systolic BP was related to BMI z score ($\beta = 6.0$, 95% CI = 2.9–9.1; $P = 0.0002$) and WHR ($\beta = 36.7$, 95% CI = 5.6–67.9; $P = 0.02$) in the obese group. Nighttime diastolic BP was related to BMI z score ($\beta = 2.4$, 95% CI = 0.3–4.4; $P = 0.02$) but not to WHR.

In the control group, only nighttime systolic BP tended to be related to BMI z score ($\beta = 2.3$, 95% CI = −0.4 to 5.1; $P = 0.10$).

**Multiple regression analyses of daytime and nighttime BP**

Nighttime systolic BP was 7.9 mm Hg higher in the obese group when compared with the control group, independent of cfPWV, logHOMA, and relevant confounders (Table 4). Nighttime systolic BP was related to cfPWV and tended to be related to logHOMA ($P = 0.06$). Nighttime diastolic BP was 2.9 mm Hg higher in the obese group when compared with the control group but was not
Nighttime systolic BP was related to logHOMA index or cfPWV when adjusted for relevant confounders. The analysis of daytime systolic BP was restricted to the obese group (n = 74) because of interactions of the group variable with other explanatory variables: group × daytime HR (P = 0.02) and group × sex (P = 0.04). In the obese group, daytime systolic BP was related to logHOMA (β = 8.0; 95% CI = 2.6–13.5; P = 0.004) and tended to be related to cfPWV (β = 3.3; 95% CI = −0.05 to 6.7; P = 0.053) when adjusted for relevant confounders (model: r² = 0.288; P = 0.0007; no interactions).

The daytime diastolic BP model was also restricted to the obese group because of an interaction of group × heart rate (P = 0.02) in pooled analysis. However, the daytime diastolic BP model including only the obese group was inconclusive (P = 0.52; r² = 0.07). The number of individuals was reduced in the models because of missing blood sample values.

In additional analyses, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and logUrine-albumin did not enter the multiple regression models for daytime or nighttime systolic BP.

No differences were found between the 2 groups in the prevalence of smoking (5 (5%) obese vs. 0 control individuals; P = 0.16) and use of medication (14 (15%) obese vs. 9 (18%) control individuals; P = 0.63). Ambulatory BP differences between the 2 groups were reproducible when restricted to nonsmokers and individuals not receiving medication. However, the relationship between nighttime systolic BP and logHOMA (P = 0.21), sex (P = 0.11), and height (P = 0.06) became insignificant.

**DISCUSSION**

The main finding of our study was that the obese group had a relatively higher nighttime than daytime BP when compared with the control group. The obesity-related elevated nighttime systolic and diastolic BP were independent of insulin resistance and arterial stiffness. Although nighttime systolic BP was related to arterial stiffness and tended to be related to insulin resistance, insulin resistance and arterial stiffness were not related.

The obesity-related elevated BP was primarily driven by the elevated nighttime BP, as also found by Aguilar et al.\(^{27}\) This was supported by our findings of increased night-to-day BP ratios in obese subjects and the association between the degree of obesity (BMI z score) and nighttime BP in the obese group. The 24-hour BP was markedly higher than the clinic BP. Although obesity might increase the chances of masked hypertension,\(^{15}\) we also found higher out-of-office BP in the control group. The observed higher out-of-office BP pattern may be because the young age of the participants.\(^{28}\) Alternatively, it is likely that BP measured after 10 minutes rest in supine position is the most relaxing moment during a day for active children, leading to relatively higher ambulatory daytime BP measurements. Part of it might be because of other differences in methodology (e.g., oscillometric algorithms or cuff bladder sizes). The method used was chosen to ensure the best suitable brachial BP measure for the noninvasive central hemodynamic measurements.\(^{16}\)

Nighttime systolic BP has been related to insulin resistance independent of BMI z score in children and adolescents in a study by Lurbe et al.\(^{1}\) In our study, nighttime systolic BP only tended to be related to insulin resistance when adjusted for obesity status. This could be because of a type II error following limited sample size. However, in other studies using multiple regression analysis, nighttime systolic BP was related to BMI z score but not to HOMA index or other metabolic measures.\(^{27,28}\) In adults, it has been shown that the relationship between insulin resistance and BP is largely, if not entirely, explained by waist circumference.\(^{30}\) In our study design, the group variable (obese vs. control) encompasses the differences in obesity measures, which is why we could not include BMI z score or WHR in the multiple regression models.

---

**Table 4.** Multiple regression models of nighttime systolic and diastolic blood pressure

<table>
<thead>
<tr>
<th></th>
<th>Nighttime systolic BP</th>
<th>Nighttime diastolic BP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>95% CI</td>
</tr>
<tr>
<td>Group, obese vs. control</td>
<td>7.9***</td>
<td>4.1 to 11.6</td>
</tr>
<tr>
<td>Age, y</td>
<td>−0.7</td>
<td>−1.9 to 0.4</td>
</tr>
<tr>
<td>Height, cm</td>
<td>0.3*</td>
<td>0.06 to 0.5</td>
</tr>
<tr>
<td>Gender, male vs. female</td>
<td>4.8**</td>
<td>1.4 to 8.1</td>
</tr>
<tr>
<td>Period dependent HR, bpm</td>
<td>0.1</td>
<td>−0.1 to 0.3</td>
</tr>
<tr>
<td>CfPWV, m/s</td>
<td>3.8*</td>
<td>0.7 to 6.8</td>
</tr>
<tr>
<td>LogHOMA index</td>
<td>5.5****</td>
<td>−0.1 to 11.1</td>
</tr>
<tr>
<td>Model, r²</td>
<td>***</td>
<td>0.355</td>
</tr>
</tbody>
</table>

The number of individuals (n = 115) was reduced in the models because of missing blood sample values. No interactions existed between group and sex with the other explanatory variables. The analysis of daytime systolic BP was restricted to the obese group because of interactions of the group variable with other explanatory variables: group × daytime HR (P = 0.02) and group × sex (P = 0.04). In the obese group, daytime systolic BP was related to logHOMA (β = 8.0; 95% CI = 2.6–13.5; P = 0.004) and tended to be related to cfPWV (β = 3.3; 95% CI = −0.05 to 6.7; P = 0.053) when adjusted for relevant confounders (model: r² = 0.288; P = 0.0007; no interactions).
The prevalence of microalbuminuria was equally low in the obese and the control group, suggesting that the obese children and adolescents in this study had not developed microvascular damage. However, the estimated glomerular filtration rate was higher in the obese group, and this might indicate an early stage of renal hyperperfusion and hyperfiltration, as can be found in non-diabetic obese children.

In some studies, increased arterial stiffness (cfPWV) has been related to insulin resistance but not in all. However, both groups found, contrary to our findings, higher cfPWV in obese individuals and even higher cfPWV in obese type 2 diabetics when compared with non-obese control individuals. This fundamental difference could be because of differences in age, ethnicity, the methodology of cfPWV, and the fact that we had no patients with type 2 diabetes in our obese group. The lower cfPWV in the obese group might be a compensatory mechanism to a hyperkinetic circulation in obese children and adolescents with a supposed higher stroke volume, cardiac output, and a higher circulating blood volume. Despite the lower cfPWV in the obese patients in our study, we found a positive relationship between cfPWV and nighttime systolic BP, as also seen in other studies. The findings suggest that the obese children in our study, despite their higher BP, might have had a too short duration or magnitude of obesity to develop subclinical organ damage (i.e., elevated cfPWV or UACR).

The lack of a relationship between cfPWV and nighttime diastolic BP may be explained by the low distending pressure on the arterial wall in the diastole, where tension is borne by elastin-distensible fibers. Contrary, a high distending pressure exists in the systole, where the tension on the arterial wall is mainly transferred to and borne by less extensible collagen fibers, making the arterial wall becomes stiffer.

We can only speculate on the possible mechanisms involved in the higher nighttime BP in the obese group, such as inferior sleep quality because of snoring or obstructive sleep apnea, a changed autonomic function, or an impaired ability to excrete sodium.

Our study has several limitations. First, HOMA index reflects insulin resistance in a fasting situation predominantly determined by hepatic insulin sensitivity and not peripheral (muscle) insulin sensitivity, whereas it does not provide information on glucose tolerance. However, HOMA index is simpler, less time consuming, and more acceptable for participants when compared with the hyperinsulinemic euglycemic clamp, which is the gold standard of assessing insulin resistance. Second, no puberty measures were collected, and these can potentially affect BP and all other measures. However, no differences in age, sex, or height were identified between the obese and the control group, suggesting a similar development in these characteristics. Third, it was difficult to recruit control individuals from the same social class as the obese group because overweight is more often seen in lower socioeconomic groups. Fourth, we cannot infer on pathophysiological mechanisms because of the cross-sectional study design.

In conclusion, the obese children and adolescents had a relatively higher nighttime than daytime BP when compared with a non-obese control group. The obesity-related elevated nighttime BP was independent of insulin resistance and arterial stiffness. Notably, the obese children had not developed subclinical organ damage as assessed by cfPWV or UACR.

In perspective of known tracking in BP, the adverse nighttime BP pattern of the obese children might contribute in the future to the adverse cardiovascular risk profile of adult obese patients. Therefore, early treatment and prevention of childhood obesity are important because they may prevent irreversible damage to the cardiovascular system.

SUPPLEMENTARY MATERIAL

Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).

ACKNOWLEDGMENTS

We would like to thank the participants and the staff at the Children's Obesity Clinic, in particularly laboratory technicians Oda Troest and Birgitte Holloese, Secretary Dorte Jensen, and database manager Arne Lykke Nielsen. For financial support we would like to thank the Health Sciences Research Foundation of Region Zealand, the Danish Heart Foundation, Kathrine og Vigo Skovgaards Fond, Det Medicinske Selskab i København, Edith og Henrik Henriksens Mindelegat, and LEO Pharma’s Travel Grant. The research activities are part of the Danish Childhood Obesity Biobank (ClinicalTrials.gov: NCT00928473) and related to TARGET (The impact of our genomes on individual treatment response in obese children) and BIOCHILD (Genetics and systems biology of childhood obesity in Italy). Part of this work was presented orally in abstract form at the 23rd Annual Scientific Meeting of the European Society of Hypertension, 15 June 2013, Milan, Italy.

DISCLOSURE

K. N. Hvidt received LEO Pharma’s Travel Grant during data collection of this study. All authors declare that there is no conflict of interests in respect to executing, analyzing, or reporting the present research project.

REFERENCES


Urbina EM, Kimball TR, Khoury PR, Daniels SR, Dolan LM. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus. J Hypertens 2010; 28:1692–1698.


